SBIR [Phase II]: Mutant Transgenic Plant Cells as a Novel Source of Drugs

Gerhardt, Greg (PI)
Littleton, John (CoI)
Lynn, Bert (CoI)

Neuroscience

Status	Finished
Effective start/end date	1/1/17 → 7/31/19

Funding

Naprogenix: $355,417.00

1 Finished

SBIR [Phase II]: Mutant Transgenic Plant Cells as a Novel Source of Drugs
Lynn, B. (PI), Gerhardt, G. (CoI) & Littleton, J. (CoI)
Naprogenix
1/1/17 → 7/31/19
Project: Research project